The addition of tocilizumab to DMARD therapy for rheumatoid arthritis: a meta-analysis of randomized controlled trials.
Tocilizumab is a humanized monoclonal antibody that binds to the interleukin-6 receptor. The purpose of this study was to evaluate the effect of adding tocilizumab to disease-modifying antirheumatic drug (DMARD) therapy for the treatment of rheumatoid arthritis (RA). We performed a meta-analysis of...
| Publicado en: | European Journal of Clinical Pharmacology Vol. 66; no. 1; pp. 49 - 60 |
|---|---|
| Autores principales: | , , , , , |
| Formato: | research systematic review Journal Article |
| Publicado: |
Springer Nature
Jan2010
|
| Acceso en línea: | Ver este registro en EBSCOhost |